Mumbai: Glenmark Pharmaceuticals, a research-led, integrated global pharmaceuticalcompany, has announced a price reduction of 27% for COVID-19 drug FabiFlu.
The new MRP is INR 75 per tabfrom the earlier INR 103 per tab.
" The price reduction has been made possible through benefits gained fromhigher yields and better scale, as both the API and formulations are made at Glenmark’s facilities in India,the benefits of which are being passed on to patients in the country," the company said in a statement.
Commenting on these developments, Alok Malik, Senior Vice President & Head – India business,Glenmark Pharmaceuticals Ltd., said, “We expect this post marketing surveillance study to shed morelight on the drug’s clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu®."
"Ourpriority from the start of this pandemic has been to offer patients in India an effective treatment forCOVID-19, while also ensuring accessibility to the masses.
"Our internal research shows us that welaunched FabiFlu® in India at the lowest market cost as compared to the cost of Favipiravir in othercountries where it is approved.
"And now we hope that this further price reduction will make it even moreaccessible for patients across the country," Malik said.